We provide you with 20 years of free, institutional-grade data for ARNA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ARNA. Explore the full financial landscape of ARNA stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| ARENA PHARMACEUTICALS INC | Sale | -3,978,540 | $24.25 | $96,479,595 | 2024-01-29 |
The information provided in this report about ARNA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Arena Pharmaceuticals, Inc(NASDAQ:ARNA) 
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clin...
Website: http://www.arenapharm.com
Founded: 1997
Full Time Employees: 363 (May 2021)
Sector: Healthcare
Industry: Biotechnology